Double-Patenting Dooms Lilly's Gemzar IP: Fed. Circ.
The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court's finding that one of Eli Lilly & Co.'s patents for cancer treatment Gemzar is invalid for double-patenting,...To view the full article, register now.
Already a subscriber? Click here to view full article